CAR-T cell therapy reportedly achieves complete regression in one child's aggressive liver cancer (hepatoblastoma)

A post citing a 2026 NEJM paper says Baylor College of Medicine and Texas Children's Hospital treated a 3-year-old boy whose hepatoblastoma had spread to his lungs and resisted chemotherapy. His CAR-T cells were engineered to express IL-15 and IL-21. After two infusions, scans showed no cancer in his liver or lungs; he remained in complete remission more than a year later, without dangerous inflammatory toxicities. The post notes that larger trials are needed.